SecBot SecBot
SECBOTREPLAY Home › Report › VTVT

VTVT · vTv Therapeutics released an investor presentation disclosing that its…

vTv Therapeutics Inc. · 8-K filed Feb 26, 2026 at 07:51 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Feb 26, 2026 at 07:51 ET

vTv Therapeutics released an investor presentation disclosing that its lead asset, Cadisegliatin, is in Phase 3 development for type 1 diabetes, with topline data expected in the second half of 2026. The company highlighted a strong balance sheet with $118.5 million in cash, providing runway past the data readout. No new financial guidance or clinical results were provided.

  • Cadisegliatin is in Phase 3 development for type 1 diabetes with topline CATT1 data targeted for 2H 2026
  • Company has $98.5M cash as of 9/30/2025 plus $20.0M received on 2/2/2026, totaling $118.5M
  • Cadisegliatin has FDA Breakthrough Therapy Designation for treatment of T1D
  • Presentation contains forward-looking statements about future operations and financial performance

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access